Lung Cancer
Conditions
Interventions
Experimental group:Screen and enroll patients. The first administration of HSPPC - 96 should be within 8 weeks after surgery (One treatment course is administered per week. Each treatment course consi
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Lung cancer patients (or puncture specimens) who have been fully evaluated clinically for surgery; Subjects voluntarily join the study and sign the informed consent form; 2. Age >=18 years old and =2g), and at least 8 needles of HSPPC-96 can be extracted; 4. KPS score >=70 points; Survival expectancy >=6 months; Good follow-up compliance; 5. Normal bone marrow reserve function and normal liver and kidney function (the following laboratory tests were performed within 7 days before the first treatment with HSPPC-96, confirming that the patient's bone marrow, liver, and kidney function met the requirements for participation in the study): absolute white blood cell value >=2.5×10^9/L; Hemoglobin > 100 g/L; Platelet count > 100×10^9/L; Total bilirubin level < 1.5 x ULN; Alanine aminotransferase/aspartate aminotransferase <2.5 x ULN; Serum creatinine < 1.5 x ULN. 6. Normal cardiac function; 7. No other anti-tumor treatment except surgery within 4 weeks before starting treatment.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. Disease recurrence before receiving autologous HSPPC-96 treatment for the first time; 3. Patients with a history of organ transplantation; 4. Patients with uncontrollable infectious diseases or other serious diseases, such as HIV positive, active hepatitis patients; 5. Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, angina pectoris that started in the last 3 months, congestive heart failure, myocardial infarction that occurred within 12 months before enrollment, severe arrhythmias requiring medication, liver, kidney failure, etc.); 6. Patients with systemic autoimmune diseases or immunodeficiency diseases; 7. Patients with allergies; 8. Chronic diseases requiring immunological agents or glucocorticoid therapy; 9. Participated in other clinical trials within the past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival (PFS);Overall Survival (OS );Quality of Life(QOL);Immunological Indices; | — |
Countries
China
Contacts
Public ContactXiao Liang
Shenzhen Second People's Hospital
Outcome results
None listed